+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders



Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders



Journal of Endocrinological Investigation 21(11): 765-770



The Nb2 cell bioassay could be a useful tool for evaluating human growth hormone (hGH) bioactivity, but is not specific for hGH since it relies on the ability of the hormone to produce effects by cross-reacting with the lactogenic receptor on Nb2 cells. We studied the biological activity of both endogenous and exogenous hGH in short patients using the Nb2 bioassay after inhibiting the mitogenic effect of the other lactogenic hormone, that is human prolactin (hPRL), by adding a specific antibody against hPRL to each assay. The in vitro study showed a significant (p<0.0001) increase in Nb2 cell proliferation when increasing concentrations of highly purified hGH were added to the cell culture. A complete inhibition of Nb2 cell replication was observed after adding a specific antibody against hGH. The in vivo study showed a significantly (p<0.0001) lower hGH bioactivity (4.90+/-0.28 ng/ml) evaluated during stimulation tests in 9 children with total idiopathic GH deficiency, mean age 9.25+/-1.99 years, in comparison with that found in 11 short children with normal growth velocity, mean age 8.22+/-1.41 years (12.25+/-1.19 ng/ml). Likewise, serum GH levels measured by immunofluorometric assay IFMA in the same serum samples were significantly (p<0.001) lower in the 9 GH-deficient (1.97+/-0.37 ng/ml) than in the 11 short children (21.85+/-2.71 ng/ml). Moreover, we evaluated GH concentrations using both IFMA and the Nb2 cell bioassay in serum samples collected from another 11 idiopathic GH-deficient children, mean age 10.71+/-1.18 years, before and then, 6 and 24 hours following the 1 st injection of r-hGH (0.1 IU/kg sc). Serum GH values measured by both IFMA and Nb2 bioassay significantly (p<0.0001) increased 6 hours after r-hGH administration and decreased to reach basal levels after 24 hours. In conclusion, the Nb2 cell bioassay with minor modifications seems to provide a specific and sensitive assessment of hGH bioactivity.

(PDF emailed within 1 workday: $29.90)

Accession: 046010137

Download citation: RISBibTeXText

PMID: 9972677


Related references

Bioactivity of serum growth hormone in children assessed by lymphoma cell bioassay. Horumon to Rinsho. Clinical Endocrinology 31(6): 577-581, 1983

Comparative study of serum human growth hormone measurement with NB2 lymphoma cell bioassay, IM-9 receptor modulation assay, and radioimmunoassay in children with disorders of growth. Journal of Clinical Endocrinology and Metabolism 58(3): 549-554, 1984

Growth hormone bioactivity evaluated by Nb-2 cell bioassay. Acta Medica Auxologica 28(3): 141-145, 1996

Comparison of bioactivity versus immunoactivity of serum growth hormone in children with growth disorders. Hormone Research 46(SUPPL 2): 16, 1996

Growth hormone assessment by radioimmunoassay and NB2 cell bioassay in children with growth failure. Acta Paediatrica Supplement 0(388): 113, 1993

Combined growth hormone-releasing hormone and growth hormone-releasing peptide-6 test for the evaluation of growth hormone secretion in children with growth hormone deficiency and growth hormone neurosecretory dysfunction. Hormone Research 70(4): 215-223, 2008

An investigation into the lability of the bioactivity of human growth hormone using the ESTA bioassay. Hormone Research 46(2): 64-73, 1996

Bioactivity of human growth hormone in serum: validation of an in vitro bioassay. Endocrinology 132(5): 2073-2082, 1993

Growth hormone secretory status evaluated by growth hormone peak after two pharmacological growth hormone release stimuli did not significantly influence the two-year catch-up growth induced by growth hormone therapy in 318 prepubertal short children with idiopathic growth retardation. Hormone Research in Paediatrics 75(2): 106-114, 2011

Effects of human growth hormone administration on growth rate and growth-stimulating activity of serum, measured by lymphocyte bioassay in hypopituitary children. Hormone and Metabolic Research 18(4): 264-267, 1986

Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technology Assessment 14(42): 1-209, Iii-Iv, 2011

Growth hormone bioactivity, insulin-like growth factors (IGFs), and IGF binding proteins in obese children. Metabolism Clinical and Experimental 47(12): 1490-1493, 1998

Prediction of the growth response in children with various growth disorders treated with growth hormone: Analyses of data from the Kabi Pharmacia International Growth study. Acta Paediatrica Supplement 0(391): 82-88, 1993

Growth hormone bioactivity and levels of growth hormone, growth hormone-binding protein, insulinlike growth factor I, and insulinlike growth factor-binding proteins in premature and full-term newborns during the first month of life. Archives of Pediatrics & Adolescent Medicine 151(2): 170-175, 1997

Effect of growth hormone releasing hormone on plasma growth hormone in relation to magnitude and duration of growth hormone deficiency in 26 children and adults with isolated growth hormone deficiency or multiple pituitary hormone deficiencies evidence for hypothalamic growth hormone releasing hormone deficiency. Journal of Clinical Endocrinology & Metabolism 58(6): 1043-1049, 1984